BioCentury
ARTICLE | Clinical News

RXI-109: Phase I started

December 10, 2012 8:00 AM UTC

RXi began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate intradermal injections of 2.5-7.5 mg RXI-109 given 3 times over 2 weeks at small incisions on separate areas of ...